About HMA

The Heads of Medicines Agencies (HMA) is a network of the heads of the National Competent Authorities (NCA) whose organisations are responsible for the regulation of medicinal products for human and veterinary use in the European Economic Area.
The HMA co-operates with the European Medicines Agency (EMA) and the European Commission in the operation of the European medicines regulatory network and it is a unique model for cooperation and worksharing on statutory as well as voluntary regulatory activities.
The HMA is coordinated and supervised by a Management Group and it is supported by several Working Groups, covering specific areas of responsibility, and by a Permanent Secretariat.
Main Activities
The HMA:
- addresses key strategic issues for the network, such as the exchange of information, IT developments and sharing of best practices
- focuses on the development, co-ordination and consistency of the European medicines regulatory system
- ensures the most effective and efficient use of resources across the network. This includes developing and overseeing arrangements for work-sharing
- co-ordinates the mutual recognition (MRP) and decentralised procedures (DCP).
Member agencies support the network by providing high-quality professional and scientific resources to all areas of medicines regulation including centralised, MRP, DCP and national procedures.
ABOUT HMA | RECENTLY PUBLISHED
Key documents list
added 01/03/2019
HMA - EMA Joint Big Data Task Force Summary Report and public consultation on...
added 26/02/2019
HMA Procedures and Governance | pdf For the Permanent Secretariat Support to the...
added 26/02/2019
Withdrawal of the UK and EU rules for Quality testing of medicinal products
added 20/02/2019
Periodic Safety Update Reporting (PSUR) - Synchronisation and Work-sharing
modified 29/11/2018
Towards electronic product information for EU medicines
added 21/11/2018
HMA/EMA Joint Task Force on Availability of authorised medicines for human and...
added 08/11/2018
Working with stakeholders to improve availability of medicines in the EU
added 08/11/2018
Safety features implementation
added 22/10/2018
The United Kingdom submitted on 29 March 2017 the notification of its intention...
added 09/10/2018
